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Abstract 
Background: Biomarker could be objective and reliable tools to predict mortality in sepsis. We explored the prog‑
nostic utilities of emerging biomarkers in septic patients and questioned whether adding biomarkers to the clinical 
variables would improve the prediction of mortality in sepsis.
Methods: This retrospective study included 157 septic patients (112 patients with sepsis; 45 patients with septic 
shock). Procalcitonin (PCT), presepsin, galectin‑3, and soluble suppression of tumorigenicity 2 (sST2) concentrations 
were analyzed in relation to the 30‑day all‑cause mortality. Their value added on top of Sequential (Sepsis‑related) 
Organ Failure Assessment (SOFA) score, high‑sensitivity C‑reactive protein, and white blood cells was also analyzed.
Results: PCT could not predict 30‑day mortality. Univariate hazard ratio [HR with 95% confidence interval (CI)] of the 
other dichotomized variables was: 1.33 (0.55–3.194) for presepsin; 7.87 (2.29–26.96) for galectin‑3; 1.55 (0.71–3.38) for 
sST2; and 2.18 (1.01–4.75) for SOFA score. The risk of 30‑day mortality increased stepwise as the number of biomarkers 
above optimal cutoff values increased, and the highest risk was observed when all four biomarkers and SOFA score 
increased (HR = 14.5). Multi‑marker approach predicted 30‑day mortality better than SOFA score [area under the 
curves (95% CI), 0.769 (0.695–0.833) vs. 0.615 (0.535–0.692)]. In reclassification analyses, adding biomarkers to clinical 
variables improved the prediction of mortality.
Conclusion: This study demonstrated a possible prognostic utility of PCT, presepsin, galectin‑3, and sST2 in sepsis. 
Multi‑marker approach could be beneficial for an optimized management of patients with sepsis.
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Background
Sepsis is a life-threatening organ dysfunction, identified 
as an acute change in total Sequential (Sepsis-related) 
Organ Failure Assessment (SOFA) score equal to or more 
than two points, caused by a dysregulated host response 
to infection, and septic shock is a subset of sepsis with 
profound circulatory, cellular, and metabolic abnormali-
ties associated with increased mortality [1]. Sepsis is 
the primary cause of death from infection, especially if 
not diagnosed and treated promptly; therefore, urgent 
attention is mandatory. The Third International Consen-
sus Definitions for Sepsis and Septic Shock (Sepsis-3) 
includes recommendations for laboratory testing to 
determine sequential organ dysfunction such as meas-
uring white blood cells (WBCs) and differential, platelet 
counts, bilirubin, and serum creatinine (sCr) to deter-
mine progression of organ dysfunction for sepsis, and 
lactate concentrations for septic shock [1, 2].
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Procalcitonin (PCT) has been known as a helpful bio-
marker for early diagnosis of sepsis, and the efficacy 
and safety of PCT-guided antibiotic treatment in criti-
cally ill patients in intensive care units (ICUs) have been 
proved [3]. In early 2016, the US Food and Drug Admin-
istration (FDA) expanded the clinical indications of PCT: 
the change in PCT concentrations over time as an aid in 
assessing the cumulative 28-day risk of all-cause mortality 
in conjunction with other laboratory findings and clini-
cal assessments for patients diagnosed with septic shock 
in the ICU or when obtained in the emergency depart-
ment or other medical wards prior to ICU admission [4, 
5]. CD14 is a glycoprotein expressed on the surface mem-
brane of monocytes/macrophages and serves as a receptor 
for lipopolysaccharides (LPSs) and LPS-binding proteins 
(LBPs). The complex of LPS-LBP-CD14 is released into 
circulation by shedding from the cell membrane, which is 
called soluble CD 14 (sCD14). Plasma protease generates 
cleaved sCD14, generating a truncated form of 64 amino 
acid residues named sCD14 subtype or presepsin [6, 7]. 
Presepsin revealed diagnostic and prognostic capacities 
to differentiate sepsis severity and to predict mortality in 
septic patients [8, 9]. Galectin-3 and soluble suppression 
of tumorigenicity 2 (sST2) have emerged as biomarkers in 
heart failure (HF) for additive risk stratification of patients 
with acute and/or chronic HF [10–12]. In addition to their 
association with HF, they can also increase in diverse non-
cardiac conditions such as infectious diseases or chronic 
kidney diseases [13–15].
Given the profound circulatory, cellular, and metabolic 
abnormalities in sepsis with multiple organ dysfunctions, 
several biomarkers, if integrated together, may present 
more objective and reliable guide for the prognosis pre-
diction in critically ill patients with sepsis. In the present 
study, we wanted to explore the prognostic utilities of 
multi-marker approach using PCT, presepsin, galectin-3, 
and sST2 in septic patients. We hypothesized that multi-
ple biomarkers, in combination or alone, would predict 
mortality in septic patients. In particular, we questioned 
whether adding biomarkers to the clinical variables, such 
as SOFA score, high-sensitivity C-reactive protein (CRP), 
and WBC would improve the prediction of mortality in 
sepsis.
Methods
Study population
From December 2014 to June 2015, a total of 273 con-
secutive patients were diagnosed as having sepsis accord-
ing to the Surviving Sepsis Campaign 2012 in the Konkuk 
University Medical Center, Seoul, Korea [16, 17]. Because 
we wanted to measure the biomarkers in leftover sam-
ples, 81 patients without available samples were excluded, 
and 192 patients with available samples were recruited. 
Because the definition of sepsis and septic shock was 
revised in early 2016, the 192 patients were recatego-
rized according to the new Sepsis-3 definition [1]; 112 
patients (58.3%) were diagnosed as having sepsis, 45 
patients (23.4%) as having septic shock; and 35 patients 
(18.2%), who could not be included in sepsis category 
according to the new definition were excluded from this 
study (Fig. 1). For the remaining 157 patients, their medi-
cal records were reviewed retrospectively for the clinical 
and demographic data, including their comorbidities and 
treatment. They received the standard-of-care treatment 
according to the guidelines [18, 19]. The characteristics of 
the study population are summarized in Table 1.
The protocol of this registry study was approved by the 
Institution Review Board (KUH1200051) of Konkuk Uni-
versity Medical Center, before collecting the first sample 
from the first patient. It was left open in the study pro-
tocol which biomarkers would be tested. This registry 
study required neither study-specific blood sampling nor 
other interventions. In all septic patients, PCT concen-
tration was measured as a routine practice together with 
CRP, WBC, and sCr for estimated glomerular filtration 
rate (eGFR) at the day when patients were diagnosed as 
having sepsis; at the same day, SOFA score was assessed, 
and residual blood samples were collected for the meas-
urement of the other biomarkers (presepsin, galectin-3, 
and sST2). Attending physicians (in ICU or ED) made 
the clinical diagnosis of sepsis according to the Surviv-
ing Sepsis Campaign 2012 and obtained blood samples 
for the routine measurements of PCT, CRP, and WBC; 
then, they informed the laboratory to store residual sam-
ples (both EDTA plasma and serum samples) from these 
blood collections. The samples were divided into small 
aliquots to avoid repeated freezing and thawing, and then 
192 paents diagnosed as having sepsis 
by Surviving Sepsis Campaign 2012 [15] 
with available samples 
157 paents diagnosed as having sepsis 
by Sepsis-3 [1] 
Excluded 81 paents 
without available samples??
Excluded 35 paents  
without sepsis 
94 paents from ICU  63 paents from ED 
112 paents 
with sepsis  
45 paents  
with sepc shock  
82 paents from MICU  
23 paents from SICU 
52 paents 
admied to wards 
273 paents diagnosed as having sepsis 
by Surviving Sepsis Campaign 2012 [15] 
Fig. 1 A flowchart for patient recruitment. Abbreviations: ICU inten‑
sive care unit, ED emergency department, MICU medical ICU, SICU 
surgical ICU
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stored at −70 °C until use. Frozen samples were thawed 
at room temperature and gently mixed up just before the 
measurement of biomarkers. Therefore, written informed 
consent from the patients was exempted.
Assays
Serum PCT concentrations were determined as routine 
practice using the Elecsys BRAHMS PCT electrochemi-
luminescence assay (BRAHMS, Henningsdorf, Germany) 
on the Roche Cobas e-System (Roche Diagnostics, Basel, 
Switzerland). The other biomarkers were claimed to be 
stable at −70  °C up to 18  months by the manufacturer 
and was measured in August 2015 in one batch according 
to the manufacturer’s recommendations.
Plasma presepsin concentrations were measured using 
an automated chemiluminescent enzyme immunoana-
lyzer, PATHFAST system (LSI Medience Co., Tokyo, 
Japan). Presepsin in the sample binds to the anti-prese-
psin antibodies to assemble an immunocomplex with 
the ALP-labeled antibodies and the mouse monoclonal 
antibody-coated magnetic particles. After 10-min incu-
bation with a chemiluminescent substrate, the lumines-
cence generated by the enzyme reaction, photomultiplier 
detected and calculated the concentration of presepsin 
[6]. Plasma galectin-3 concentrations were measured 
using the VIDAS automated enzyme-linked fluorescent 
assay (bioMérieux, Marcy-l’Etoile, France). Serum sST2 
concentrations were measured using the Presage ST2 
Assay (Critical Diagnostics, San Diego, CA, USA). It is 
an enzyme-linked immunosorbent assay with mouse 
monoclonal anti-human sST2 antibodies coated 96-well 
microtiter plate [20]. The manufacturer-claimed measur-
able range of PCT, presepsin, galectin-3, and sST2 assays 
was 0.02–100 ng/mL, 20–20,000 pg/mL, 20–20,000, and 
3.1–250  ng/mL, respectively. Coefficient of variation 
(CV) (%) of each assay was determined in our labora-
tory according to the CLSI document EP15-A2 [21]. The 
CVs were tested at two levels by running three replicates 
over five days; the CV of PCT, presepsin, galectin-3, 
and sST2 assays were <2.47%, <5.0%, <4.9%, and <3.0%, 
respectively.
The sCr was measured by the kinetic Jaffe method 
using Roche CREA (Roche Diagnostic, Mannheim, Ger-
many) traceable to isotope dilution mass spectrometry 
(IDMS) on an automated chemistry analyzer TBA-200 FR 
(Toshiba Co., Tokyo, Japan). Dynamic measuring range 
was 0.2–25 mg/dL, and the mean within-laboratory pre-
cision of the sCr assay was 1.35% during the study period. 
eGFR was calculated by using the IDMS-traceable four-
variable modification of diet in renal disease study equa-
tion [22]; GFR = 175 × sCr−1.154 × Age−0.203 × 0.742 [if 
female]. The high-sensitivity CRP was measured by CRP-
Latex (II) X2 (Denka Seiken Co., Tokyo, Japan) by latex 
agglutination method on TBA-200 FR. Its measurement 
range was 0.01–35 mg/dL, and the mean within-labora-
tory precision was 2.0% during the study period. WBC 
was measured by an automated hematology analyzer XN 
modular system (Sysmex, Kobe, Japan). Its measurement 
Table 1 Characteristics of the study population
* Multiple infections were observed in 112 patients (71.3%), and 20 patients 
(12.7%) had radiographically proven infection without pathogen isolation. The 
number of type of infections and proportion of infection episode with isolated 
pathogen is based on each infection episode
IQR interquartile range, eGFR estimated glomerular filtration rate, MDRD 
modification of diet in renal disease, SOFA sequential organ failure assessment, 
PCT procalcitonin, sST2 soluble suppression of tumorigenicity 2
Variable All patients (N = 157)
Sepsis criteria 157 (100.0)
 Sepsis, N (%) 112 (71.3)
 Septic shock, N (%) 45 (28.7)
Patients enrollment
 Intensive care unit, N (%) 94 (59.9)
 Emergency room, N (%) 63 (40.1)
Age (years), median [IQR] 70 [57.7–77.0]
Males, N (%) 95 (60.5)
Hospital stay (days), median [IQR] 16 [8–40]
In‑hospital mortality, N (%) 40 (25.5)
30‑day mortality, N (%) 34 (21.7)
Comorbidities
 Hemato‑oncologic, N (%) 31 (19.6)
 Pulmonary, N (%) 29 (18.6)
 Cerebrovascular, N (%) 28 (17.5)
 Renal and genitourinary, N (%) 19 (12.4)
 Gastrointestinal, N (%) 18 (11.3)
 Cardiovascular, N (%) 16 (10.3)
 Others, N (%) 16 (10.3)
Type of infections/proportion of infection episodes with isolated  
pathogens*
 Bacteremia, N (%)/% 90 (57.3)/100%
 Respiratory infection, N (%)/% 102 (65.0)/88.2%
 Urinary infection, N (%)/% 55 (35.0)/100%
 Gastrointestinal infection, N (%)/% 26 (16.6)/46.2%
 Others, N (%)/% 4 (2.5)/100%
eGFR by MDRD Study equation  
(mL/min/1.73 m2), median [IQR]
44.45 [20.83–81.33]
SOFA score range 2–11
2 (45, 28.7%); 3 (32, 20.4%); 
4 (26, 16.6%); 5 (14, 8.9%); 
6 (13, 8.3%); 7 (12, 7.6%);  
8 (6, 3.8%); 9 (3, 1.9%);  
10 (3, 1.9%); 11 (3, 1.9%)
CRP (mg/dL), median [IQR] 12.54 [7.22–22.0]
WBC (× 109/L), median [IQR] 12.47 [8.18–17.10]
PCT (ng/mL), median [IQR] 6.19 [2.25–21.99]
Presepsin (pg/mL), median [IQR] 2714.0 [1479.3–4129.7]
Galectin‑3 (ng/mL), median [IQR] 30.8 [17.9–58.5]
sST2 (ng/mL), median [IQR] 214.5 [133.6–238.8]
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range was 0.00–239.05  ×  109/L, and the mean within-
laboratory precision was 0.85% during the study period.
Statistical analysis
Data were expressed as median and interquartile range 
(IQR) or number and percentage. Groups were compared 
using Mann–Whitney U test. Receivers operating char-
acteristic (ROC) curves of each biomarker and SOFA 
score were compared to derive optimal cutoff values for 
the prediction of 30-day all-cause mortality. Optimal 
cutoff values meant where the sum of false positive and 
false negative results were lowest. Areas under the curves 
(AUC) were reported with their 95% confidence interval 
(CI). Each biomarker and SOFA score were dichotomized 
(above and below cutoffs) according to the respective 
optimal cutoff values for 30-day all-cause mortality. 
Cox proportional hazard regression was used to analyze 
the effect of biomarkers and SOFA score on 30-day all-
cause mortality; univariate hazard ratio (HR, with 95% 
CI) of the dichotomized variables was obtained. All 157 
patients were divided into six groups (from 0 to 5) based 
on the frequency of above cutoff values, and each group 
was compared according to the 30-day mortality using 
Kaplan–Meier survival curves and HR (with 95% CI). 
With dichotomized variables using respective optimal 
cutoff values for 30-day mortality, ROC curves of SOFA 
score, combined biomarkers, and combination of SOFA 
score and biomarkers were generated again, and their 
AUC were compared for the prognostic utility of multi-
marker approach. Reclassification analyses using net 
reclassification improvement (NRI) and integrated dis-
crimination improvement (IDI) were used to assess the 
added value of multi-marker approach on top of SOFA 
score, CRP, and WBC; NRI and IDI values were analyzed 
with their 95% CI. For the statistical analyses, MedCalc 
Software (version 15.8, MedCalc Software, Mariakerke, 
Belgium) and R version 3.3.1 (The R Foundation for Sta-
tistical Computing, Vienna, Austria) were used. The P 
values were not adjusted for multiple comparisons and, 
therefore, were only descriptive.
Results
The concentrations of PCT, presepsin, galectin-3, and 
sST2 are presented in Table 1. Presepsin, sST2, and SOFA 
score were comparable for the prediction of 30-day all-
cause mortality, and galectin-3 was superior to them with 
fair performance. PCT could not predict 30-day mortal-
ity. The optimal cutoff values for 30-day mortality were as 
follows: PCT, 0.16 ng/mL; presepsin, 2,455 pg/mL; galec-
tin-3, 28.4 ng/mL; sST2, 215.2 ng/mL; and SOFA score, 7 
(Fig. 2).
When the biomarkers and SOFA score were compared 
between the survivors and non-survivors, except for PCT 
concentration, the others were higher in the non-survi-
vors than in the survivors (all P < 0.002), and univariate 
HR of the biomarkers of interest and SOFA score are 
given in Table 2.
Multi-marker approach using above cutoff values of 
each biomarker and SOFA score showed differences for 
the prediction of 30-day morality. Mortality rate in each 
group showed a stepwise increase: 0% in group 0; 6.3% 
in group 1; 10.7% in group 2; 17.6% in group 3; 35.1% in 
group 4; and 62.5% in group 5. Group 5 showed higher 
HR compared with groups 1, 2, and 3; 14.5 (95% CI 3.2–
64.7), 9.6 (95% CI 2.1–42.8), and 6.1 (95% CI 1.4–26.0), 
respectively (Fig.  3a). In ROC curve analysis, multi-
marker approach predicted the 30-day mortality better 
than SOFA score [AUC = 0.769 (95% CI 0.695–0.833) vs. 
AUC = 0.615 (95% CI 0.535–0.692)]. Addition of SOFA 
score on multi-markers showed similar findings (Fig. 3b).
In reclassification analyses, the four biomarkers added 
on top of SOFA score, CRP, and WBC showed increased 
prognostic values than SOFA score, CRP, and WBC 
alone. Among the four biomarkers, only galectin-3 
showed added values on top of SOFA score, CRP, and 
WBC (Fig. 4).
Discussion
This study evaluated the prognostic utility of PCT, pre-
sepsin, galectin-3, and sST2, and their combinations in 
septic patients. As new sepsis definition became available 
in early 2016, our study population, who were recruited 
according to the Surviving Sepsis Campaign 2012, were 
reclassified as sepsis and septic shock; the patients who 
could not fulfill the new criteria were excluded [1, 16, 17].
In the present study, new biomarkers of presepsin, 
galectin-3, and sST2 were better than PCT for the predic-
tion of 30-day mortality, and differently from PCT, they 
were higher in non-survivors than in survivors. SOFA 
score also showed such a difference. Of note, galectin-3 
was the strongest risk predictor of 30-day mortality.
PCT is the US FDA-approved biomarker for risk assess-
ment of septic patients, and its increase over time can be 
an aid in assessing the cumulative 28-day risk of all-cause 
mortality for patients diagnosed with septic shock [4, 5]. 
Presepsin has shown good diagnostic performance in pre-
dicting bacteremia and bacterial DNAemia in patients 
with suspected sepsis, and both PCT and presepsin have 
shown similar performances for predicting 28-day mortal-
ity [7, 23, 24]. In our data, PCT was the only marker that 
showed no concentration difference between the survivors 
and non-survivors and no predictive power for 30-day 
mortality. These findings suggest that PCT is less prognos-
tic than the other three biomarkers and SOFA score.
According to the Sepsis-3 definition, at least two inde-
pendent progressive organ dysfunctions are required 
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for the diagnosis of sepsis, and septic shock is a subset 
of sepsis with underlying circulatory and cellular abnor-
malities. Both galectin-3 and sST2 were introduced as 
cardiac biomarkers, and they could predict worsened 
outcome of HF [10–12, 25, 26]. In addition to HF, galec-
tin-3 and sST2 are independent biomarkers of inflamma-
tion, fibrosis, and cardiac stress. They are not specific for 
a distinct medical condition but rather represent general 
marker of mortality [13, 15, 27]. Our findings are in line 
with the previous findings and new sepsis definition, 
and galectin-3 and sST2 may have reflected circulatory 
abnormalities in this study population.
The present study addressed that multi-marker 
approach may be an aid for the prognosis prediction 
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Variable AUC (95% CI) Opmal cut-off 
value
Sensivity of opmal cut-off 
value (%, 95% CI)
Specificity of opmal cut-off 
value (%, 95% CI)
PCT 0.513 (0.432 – 0.594) 0.16 ng/mL 100.0 (89.7 – 100.0) 10.57 (5.7 – 17.4)
Presepsin 0.684 (0.605 – 0.756) 2,455 pg/mL 76.5 (58.8 – 89.3) 53.7 (44.4 – 62.7)
Galecn-3 0.776 (0.702 – 0.838) 28.4 ng/mL 91.2 (76.3 – 98.1) 56.9 (47.7 – 65.8)
sST2 0.673 (0.594 – 0.746) 215.2 ng/mL 73.5 (55.6 – 87.1) 57.7 (48.5 – 66.6)
SOFA score 0.686 (0.607 – 0.758) 7 32.4 (17.4 – 50.5) 96.8 (91.9 – 99.1)
Fig. 2 Comparison of the receiver operating characteristics curves to predict 30‑day mortality in sepsis. For each biomarker and SOFA score, opti‑
mal cutoff values to predict 30‑day mortality were obtained. Abbreviations: see Table 1
Table 2 Comparison of PCT, presepsin, galectin-3, sST2, and SOFA score according to the 30-day mortality
Data are expressed as median (interquartile range)
* Mann–Whitney U test
a Cox proportional hazard regression using dichotomized variables according to the respective optimal cutoff values for 30-day all-cause mortality derived from 
receiver operating characteristics curve analysis. HR was not analyzed for procalcitonin that showed no difference between survivors and non-survivors
See Table 1; HR hazard ratio, NS not significant
Total (N = 157) 30-day mortality
Survivor (N = 123) Non-survivor (N = 34) P* HR (95% CI)a P
Procalcitonin (ng/mL) 6.19 (2.24–22.39) 6.61 (2.22–20.78) NS – –
Presepsin (pg/mL) 2,310.0 (1375.8–3920.2) 3,549.0 (2493.7–8242.7) 0.0011 1.33 (0.55–3.19) NS
Galectin‑3 (ng/mL) 24.5 (16.7–47.5) 58.6 (37.0–82.2) <0.0001 7.87 (2.29–26.96) 0.0011
sST2 (ng/mL) 209.5 (116.9–236.9) 237.3 (208.8–253.3) 0.0020 1.55 (0.71–3.38) NS
SOFA score 3 (2–5) 5 (3–8) 0.0007 2.18 (1.01–4.75) 0.0496
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1, N = 32, events = 2 (6.3%)
2, N = 28, events = 3 (10.7%)
3, N = 34, events = 6 (17.6%)
4, N = 37, events = 13 (35.1%)
5, N = 16, events = 10 (62.5%)
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0 - - - - -
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6.2
(2.1 – 17.9)
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(1.4 – 26.0)
4 2.3(0.5 – 10.4) Hazard ratios with 95% CI
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SOFA score vs. PCT + Presepsin + Galectin-3 + sST2, P = 0.0020
SOFA score vs. SOFA score + PCT + Presepsin + Galectin-3 + sST2, P < 0.0001
Variable AUC (95% CI)
SOFA score 0.615 (0.535 – 0.692)
PCT + Presepsin + Galecn-3 + sST2 0.769 (0.695 – 0.833)
SOFA score + PCT + Presepsin + Galecn-3 + sST2 0.776 (0.703 – 0.839)
a
b
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in septic patients. Our results are novel with respect to 
combined use of PCT, presepsin, galectin-3, and sST2 
as markers of sepsis per se and organ dysfunction. We 
also combined these biomarkers with clinical variables, 
representatively SOFA score. As the number of above 
cutoff values increased from 0 to 5, the 30-day mortality 
SOFA + PCT
0.004 (-0.005 – 
-0.062 (-0.215 – 
SOFA + Presepsin
-0.007 (0.000 – 
-0.067 (-0.279 – 
SOFA + Galecn-3
0.074 (0.004 – 
0.324 (0.108 – 
SOFA + sST2
0.013 (-0.007 – 
0.076 (-0.188 – 
SOFA + Four biomarkers
0.101 (0.023 – 
0.234 (0.053 – 
CRP + 
0.001 (-0.004 – 
0.086 (-0.164 – 
CRP +
0.066 (-0.003 – 
0.199 (-0.005 – 
CRP + Galecn-
0.163 (0.036 – 
0.423 (0.145 – 
CRP +
0.058 (-0.008 – 
0.115 (-0.105 – 
CRP + Four
0.181 (0.069 – 
0.427 (0.099 – 
WBC + 
IDI 0 (-0.003 – 
NRI 0.156 (-0.197 – 
WBC +
IDI 0.061 (-0.012 – 
NRI 0.147 (-0.058 – 
WBC + Galecn-
IDI 0.158 (0.044 – 
NRI 0.446 (0.200 – 
WBC +
IDI 0.041 (-0.006 – 
NRI 0.153 (-0.147 – 
WBC + Four biomarkers
IDI 0.182 (0.075 – 
NRI 0.413 (0.154 – 
SOFA + WBC + CRP + 
0 (-0.003 – 0.053)
0.156 (-0.197 – 0.356)
SOFA + WBC + CRP + 
0.061 (-0.012 – 0.153)
0.147 (-0.058 – 0.366)
SOFA + WBC + CRP + Galecn-
0.158 (0.044 – 0.290)
0.446 (0.200 – 0.648)
SOFA + WBC + CRP + 
0.041 (-0.006 – 0.145)
0.153 (-0.147 – 0.340)
SOFA + WBC + CRP + 
0.182 (0.075 – 0.337)
0.413 (0.154 – 0.630)
Esmated value (95% CI)
Fig. 4 Multimarker approach to predict 30‑day mortality in sepsis. Reclassification analyses of biomarkers and SOFA score using NRI and IDI. The 
rhombi mean estimated values and lines mean 95% CI. Abbreviations: PCT procalcitonin; sST2, soluble suppression of tumorigenicity 2, ROC receiver 
operating characteristics, SOFA sequential organ failure assessment, IDI integrated discrimination improvement, NRI net reclassification improve‑
ment, CRP C‑reactive protein, WBC white blood cells, CI confidence interval
(See figure on previous page.) 
Fig. 3 Multimarker approach to predict 30‑day mortality in sepsis. a Multi‑marker approach using above optimal cutoff values of PCT, presepsin, 
galectin‑3, sST2, and SOFA score for the prediction of 30‑day all‑cause mortality. b Multi‑marker approach using multivariate ROC curve analysis for 
the prediction of 30‑day all‑cause mortality. Abbreviations: PCT procalcitonin; sST2, soluble suppression of tumorigenicity 2, ROC receiver operat‑
ing characteristics, SOFA sequential organ failure assessment, IDI integrated discrimination improvement, NRI net reclassification improvement, CRP 
C‑reactive protein, WBC white blood cells, CI confidence interval
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increased in a stepwise pattern. Of note, group 0 had no 
event of mortality, and group 5 showed higher HR com-
pared with groups 1, 2, and 3.
SOFA score was suggested 20  years ago to describe 
multiple organ failures in sepsis, using six different sub-
scores (ranging from 0 to 4) for each organ. In general, 
there was an increasing mortality rate with a greater 
SOFA score and a good distribution of patient numbers 
among the different scores. However, SOFA scoring sys-
tem had acknowledged limitations in terms of variables 
used and mortality discrimination, especially for car-
diovascular and coagulation systems [28]. Accordingly, 
there is a room for further improvement of this scoring 
system with incorporation of promising biomarkers. Our 
data showed a significantly added value of promising bio-
markers on top of SOFA score as well as established bio-
markers of CRP and WBC. Of note, galectin-3 showed 
the strongest prognostic value added on top of clini-
cal variables and established biomarkers. Several recent 
studies also explored diagnostic or prognostic usefulness 
of combined biomarkers in heterogeneous, critically ill 
settings [29–31].
This study has several limitations. We focused on the 
comparison of PCT, presepsin, galectin-3, and sST2 con-
centrations with 30-day mortality; so, we did not inves-
tigate the distribution of these biomarkers in relation to 
the specific bacteriological identification or antibiotic 
consumption. In addition, we did not perform follow-up 
measurements of these biomarkers. Due to the limited 
volume of blood samples, we could not measure other 
biomarkers, including natriuretic peptides, high-sensitive 
cardiac troponins, interleukin-6, which are known to be 
strong prognosticators in septic patients. We used SOFA 
score only; we did not use other clinical variables, such 
as Simplified Acute Physiology Score (SAPS) II, SAPS 
III, and/or Acute Physiology and Chronic Health Evalu-
ation II scores. Further studies are encouraged to eluci-
date the clinical usefulness of the combination of these 
biomarkers.
Conclusion
In conclusion, this study explored the prognostic utility 
of PCT, presepsin, sST2, and galectin-3 in septic patients. 
Compared with PCT, the other novel biomarkers showed 
superior prognostic performances, and their combined 
use reflected clinical outcome. Multi-marker approach 
using PCT, presepsin, sST2, and galectin-3 seems to be 
objective and useful for the prognosis prediction in septic 
patients.
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